Vaxcyte Inc (PCVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.75B
Last updated: Nov 17, 2026 at 4:33 PM ET
Vaxcyte Inc (PCVX) Statistics
Vaxcyte (PCVX) has a market cap of $9.75B and an enterprise value of $9.63B. Its share count is up 9.33% from a year earlier.
Total Valuation
Enterprise value is 1.29% below the market cap, as cash exceeds debt.
| Market Cap | $9.75B |
|---|---|
| Enterprise Value | $9.63B |
| Latest price (Nov 17, 2026) | $59.40 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 22.00% over 52 weeks and trades 4.55% below its 50-day average.
| Beta (1Y) | 1.28 |
|---|---|
| 52-Week Change | +22.00% |
| 1-Month Change | -6.72% |
| 3-Month Change | -6.16% |
| 6-Month Change | +21.77% |
| 5-Year Change | +165.09% |
| Total Return (1Y) | +22.00% |
| Total Return (3Y CAGR) | +4.90% |
| Total Return (5Y CAGR) | +19.36% |
| Return vs SPY (1Y) | +8.37% |
| Max Drawdown (1Y) | -27.95% |
| Max Drawdown (3Y) | -76.22% |
| Sharpe Ratio (1Y) | 0.34 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $62.23 |
| 200-Day Average | $57.75 |
| 52-Week Range | $42.40 to $90.75 |
| RSI (14 Days) | 43.0 |
| Average Volume (20 Days) | 1.76M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.56x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.56x |
|---|---|
| Quick Ratio | 4.56x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -46.14% over the last 12 months, against a 5-year average of -26.74%.
| Return on Equity (ROE) | -46.14% |
|---|---|
| Return on Assets (ROA) | -38.42% |
| ROE (5Y Average) | -26.74% |
| ROA (5Y Average) | -24.08% |
| ROIC (5Y Average) | -26.07% |
Scores
PCVX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | $4.99M |
| Operating Income | -$1.23B |
| Pretax Income | -$1.15B |
| Net Income | -$1.15B |
| Reported EPS (TTM) | -$8.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 83.28% of the $2.99B in total assets.
| Cash and Equivalents | $125.47M |
|---|---|
| Total Debt | $0 |
| Net Cash | $125.47M |
| Net Cash Per Share | $0.84 |
| Working Capital | $1.05B |
| Shareholder Equity | $2.49B |
| Book Value Per Share | $16.72 |
| Total Assets | $2.99B |
| Total Liabilities | $499.92M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $12.41M of capital spending, operating cash flow left -$974.42M of free cash flow.
| Operating Cash Flow | -$962.01M |
|---|---|
| Capital Expenditures | $12.41M |
| Free Cash Flow | -$974.42M |
| FCF Per Share | -$6.19 |
| Depreciation and Amortization | $26.84M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +28.89% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +28.89% |
Dividends and Yields
PCVX does not pay a dividend. Its free cash flow yield is -11.02%.
| FCF Yield | -11.02% |
|---|---|
| Buyback Yield | -7.12% |
| Shareholder Yield | -7.12% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PCVX
What is PCVX's market cap?
Vaxcyte has a market cap of $9.75B. Its enterprise value, which adds debt and subtracts cash, is $9.63B.
How many shares of PCVX are outstanding?
Vaxcyte has 148.91M shares outstanding. The count is up 9.33% from a year earlier.
Does PCVX pay a dividend?
No. Vaxcyte does not pay a dividend.
How much debt does PCVX have?
Vaxcyte has $0 of total debt and $125.47M of cash and equivalents, a net cash position of $125.47M.
PCVX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors